World Holdings (2429) · RiskMaterialised
Postponement of scheduled clinical trials
First written in FY2016-Q2. 2 of 3 entries say "Materialised", first in FY2016-Q2. Latest entry: FY2018-Q2.
3entries
3years
0from disclosures
How it moved
Same theme, other companies
Risk of CRO Business Stagnation Due to Postponement or Loss of Contracted Clinical Trial ProjectsA theme 1 companies write about · 1 as a headwind · 0 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2018-Q2MaterialisedAnnual report
「一方で、臨床試験受託事業（ＣＲＯ）を行っているＤＯＴワールド㈱においては、大型受託案件の失注等があった中で、社員育成と組織の見直しに、セグメント利益の押し下げ要因になることも見越した上で投資をしたことにより一時的な減益となっております。」
ＣＲＯ事業で大型受託案件の失注が発生し、社員育成・組織見直しへの投資と合わせて一時的な減益要因となった。 - FY2017-Q1RestatedAnnual report
「Although some scheduled projects were postponed to the next fiscal year, DOT World Co., Ltd., which operates a CRO business, worked to recruit monitors and further strengthen its internal platform.」
予定プロジェクトの次期延期が引き続き発生している一方、モニター採用と社内基盤強化を進めている。 - FY2016-Q2MaterialisedAnnual report
「DOT International Co., Ltd., which operates a CRO business, experienced a postponement of a trial that had initially been scheduled. However, its ongoing company-sponsored clinical trial projects progressed steadily and the business remained solid.」
Although a scheduled trial was postponed, ongoing company-sponsored clinical trials progressed steadily.